SARS-CoV-2 Interaction with Human DNA Methyl Transferase 1: A Potential Risk for Increasing the Incidence of Later Chronic Diseases in the Survived Patients

• Published in: International journal of preventive medicine Vol. 13; no. 1; p. 23
• Main Authors: Fakhrolmobasheri, Mohammad, Shiravi, Amirabbas, Zeinalian, Mehrdad
• Format: Journal Article
• Language: English
• Published: Iran Wolters Kluwer - Medknow 01.01.2022; Wolters Kluwer Medknow Publications
• Subjects: Brief Communication; chronic diseases; covid-19; dna methyl transferase; epigenetics; sars-cov-2; COVID-19; Chronic diseases; DNA Methyl Transferase; SARS-CoV-2; epigenetics
• ISSN: 2008-7802; 2008-8213
• DOI: 10.4103/ijpvm.IJPVM_628_20

Currently, the COVID-19 pandemic is the most discussed subject in medical researches worldwide. As the knowledge is expanded about the disease, more hypotheses become created. A recent study on the viral protein interaction map revealed that SARS-CoV-2 open reading frame 8 (ORF8) interacts with human DNA methyl transferase1 (DNMT1), an active epigenetic agent in DNA methylation. Moreover, DNMT1 is a contributor to a variety of chronic diseases which could cause some epigenetic dysregulation in infected cells, especially leukocytes, pancreatic beta, and endothelial cells. Regarding the fact that epigenetic alterations have a partial, but not completely reversible phenomena, it raises the question that if this interaction may cause long-term complications such as diabetes, atherosclerosis, cancer, and autoimmune diseases. Accordingly, long follow-up studies on the recovered patients from COVID-19 are recommended.